Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Beijing Tong Ren Tang Chinese Medicine Co ( (HK:3613) ) is now available.
Beijing Tong Ren Tang Chinese Medicine Company Limited has proposed a final ordinary cash dividend of HKD 0.37 per share for the financial year ended 31 December 2025, highlighting its intention to return profits to shareholders. The dividend is subject to shareholder approval on 10 June 2026 and, if approved, shares will trade ex-dividend on 12 June, with the books closing from 16 to 18 June and payment scheduled for 26 June 2026, framing a clear timetable for investors to secure entitlement.
The announcement, which specifies that the dividend will be paid in Hong Kong dollars without any listed withholding tax implications, underlines the company’s continued commitment to consistent shareholder distributions. By setting out the key record, transfer, and payment dates, Beijing Tong Ren Tang Chinese Medicine provides clarity to the market and supports planning for both long-term investors and income-focused stakeholders.
The most recent analyst rating on (HK:3613) stock is a Hold with a HK$9.00 price target. To see the full list of analyst forecasts on Beijing Tong Ren Tang Chinese Medicine Co stock, see the HK:3613 Stock Forecast page.
More about Beijing Tong Ren Tang Chinese Medicine Co
Beijing Tong Ren Tang Chinese Medicine Company Limited operates in the traditional Chinese medicine sector, focusing on the manufacture and sale of Chinese herbal products and related healthcare remedies. Listed in Hong Kong, the company targets both domestic and overseas markets seeking traditional therapeutic and wellness solutions.
Average Trading Volume: 948,551
Technical Sentiment Signal: Sell
Current Market Cap: HK$7.08B
Learn more about 3613 stock on TipRanks’ Stock Analysis page.